Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Polivy(polatuzumab vedotin-piiq)泊洛妥珠单抗

The MMAE conjugate Polivy (polatuzumab vedotin) is the first ADC drug approved to target CD79b. In June 2019, Polivy was approved by the US FDA in combination with BR therapy for the treatment of relapsed and refractory diffuse large B-cell lymphoma (R/R DLBCL) who have received at least 2 therapies; 2021 In March 2020, Polivy was approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) to combine bendamustine and rituximab (BR therapy) for the treatment of relapsed or refractory (R/R) diffuse large B cell lymphoma (DLBCL).

Share:

Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.